Sezolamide, a potent topical carbonic anhydrase inhibi tor previously known as MK-417, was studied to deter mine its ocular hypotensive activity in patients with elevated intraocular pressure while on continuing ther apy with topical timolol. This was a three-centre, double masked, randomised, placebo-controlled, parallel study in 36 patients with bilateral primary open angle glau coma or ocular hypertension on therapy receiving 0.5% timolol twice daily, with a morning intraocular pressure greater than or equal to 22 mmHg in both eyes 2-4 hours following an 8 a.m. dose of timolol. Sezolamide 1.8% or placebo twice daily was added to treatment with timolol on the evening of day 1 and continued for 2 weeks.
SUMMARY
Sezolamide, a potent topical carbonic anhydrase inhibi tor previously known as MK-417, was studied to deter mine its ocular hypotensive activity in patients with elevated intraocular pressure while on continuing ther apy with topical timolol. This was a three-centre, double masked, randomised, placebo-controlled, parallel study in 36 patients with bilateral primary open angle glau coma or ocular hypertension on therapy receiving 0.5% timolol twice daily, with a morning intraocular pressure greater than or equal to 22 mmHg in both eyes [2] [3] [4] hours following an 8 a.m. dose of timolol. Sezolamide 1.8% or placebo twice daily was added to treatment with timolol on the evening of day 1 and continued for 2 weeks.
Twelve-hour diurnal curves were performed before the study on day 1 (timolol alone) and on day 15 . Intraocular pressure measurements were also taken on days 2 and 8 at 8 a.m. and 9 a.m. Patients who received timolol and sezolamide showed additional intraocular pressure reductions from day 1 (timolol alone) of 8.0 to 15.5%, which were significant at all times. At hours 1, 2, 4 and 8 the reductions in intraocular pressure observed in the group receiving sezolamide and timolol were significantly greater than those in the group receiving timolol and placebo.
Over the past 5 years. significant progress has been made in developing a potent topically active carbonic anhydrase inhibitor. The racemate MK-927 was the first topical car bonic anhydrase inhibitor to demonstrate substantial pro longed clinically significant activity in patients with bilateral primary open angle glaucoma and ocular hypertension.I-' Sezolamide. previously known as MK-417. is the more potent of the two stereo isomers of MK-927 in inhibiting human carbonic anhydrase isoenzyme II. the isoenzyme found in ciliary processes. Sezolamide. the S-enantiomer of MK-927. has demonstrated activity in I'itro approxi mately 80 times that of the R-enantiomer of MK-927 (con centrations of 0.54 nmolll and 44 nmolli. respectively. inhibiting activity of human carbonic anhydrase isoen zyme II by 50%). h Clinically, sezolamide has also demon strated greater activity than MK-927 both after single-dose and after twice daily administration in patients. In a three-period, single-dose crossover study in patients . a peak mean percentage decrease in intraocular pressure from predose levels of 24% was demonstrated after 1% sezolamide versus a 20°1c decrease after 1% MK-927. 7 A maximum intraocular pressure lowering activity from time-matched baseline diurnal curve values of about 20% was observed after multiple-dose twice daily administration of I.R% sezolamide in patients with primary open angle glaucoma or ocular hypertension.x However. the overall duration of action was insufficient for twice daily administration.
This study was undertaken to explore the potential effi cacy of sezolamide as adjunctive therapy. In particular. we investigated the degree of additional intraocular pressure lowering achieved by sezolamide in patients with elevated intraocular pressure while on treatment with topical tim-0101 maleate. A twice daily dosing regimen was selected in order to study whether the three times daily frequency necessary when used as monotherapy') could be reduced with concomitant use of a beta-blocker. To our knowl edge. this is the first study to investigate the additive hypo tensive effect of timolol maleate and an active topical carbonic anhydrase inhibitor in patients with glaucoma.
PATIENTS AND METHODS

Materials
All patients received 0.50/1' timolol maleate ophthalmic solution. In addition patients were allocated to receive I.R% sezolamide hydrochloride ophthalmic solution or vehicle (placebo). The ophthalmic formulation of sezola-mide utilised in this study was isotonic, buffered at pH 5.2, preserved with benzalkonium chloride, and included 0.5% hydroxyethyl cellulose as a viscosity enhancer.
Patient Selection and Entry
This study was approved by the Ethical Review Board at each participating hospital and each patient gave informed consent before entering the study. Patients were recruited if they had a diagnosis of bilateral primary open angle glaucoma or ocular hypertension and were between 45 and 85 years of age. Females were required to be either postmenopausal or sterilised. Ocular hypotensive therapy was to include an ophthalmic beta-blocker for at least 5 weeks prior to entry into the study and to consist solely of 0.5% timolol twice daily at 8 a.m. and 8 p.m. during the last 3 weeks of this period. This last 3 weeks provided a run-in period on timolo!. In order to proceed into the 2-week adjunctive therapy study patients were required to have an intraocular pressure greater than or equal to 22 mmHg in both eyes simultaneously between 2 and 4 hours following the 8 a.m. dose of timolol administered by the investigator on the last day of the run-in period.
Exclusion criteria included inability to discontinue con comitant systemic or dermatological medication known to affect intraocular pressure, any concurrent ocular therapy other than the study drug, a history of intraocular surgery, best corrected Snellen visual acuity at distance equal to or worse than 20/1 00 in both eyes, recent signs of ocular infection or inflammation, and any contraindication to therapy with a beta-blocker. Furthermore, patients with a history of poor ocular response to previous therapy with an oral or topical carbonic anhydrase inhibitor or an oph thalmic beta-blocker were excluded from this study.
Study Design
This was a three-centre, double-masked, randomised, pla cebo-controlled, parallel study. All patients received 0.5% timolol maleate at 8 a.m. and 8 p.m. followed by 1.8% sezolamide hydrochloride or placebo (vehicle) admin istered to each eye at 8: 10 p.m. and 8: 10 a.m. The first dose was given at 8: 10 p.m. on day I. Tr eatment with timolol and the study drug continued for 14 days. The final dose of both was given on the morning of day 15.
A pre study 12-hour diurnal intraocular pressure curve was performed on day I. This provided a baseline diurnal curve after 3 weeks on timolo!. Intraocular pressure measurements were taken immediately prior to the timolol dose at 8 a.m. and then every 2 hours until 8 p.m. The patient was then observed for 30 minutes following the first dose of study drug at 8: to p.m., returning on days 2 and 8 for intraocular pressure measurements at 8 a.m. (before the timolol dose) and 9 a.m. (I hour after the dose). On day 15, intraocular pressure was again measured immediately prior to the timolol dose at 8 a.m. and then every 2 hours until 8 p.m.
Within each centre. all measurements of intraocular pressure for a given patient were performed by the same person using the same Goldmann applanation tonometer.
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A fluorescein-benoxinate solution was instilled to permit the examination.
Patients were closely monitored throughout the study with evaluations of symptoms, visual acuity, and external and anterior segment signs. Both prestudy and post study examinations included dilated ophthalmoscopy and visual field examination.
Statistical Methods
The primary variables of interest were change and per centage change in intraocular pressure from prestudy values at the same timepoint. Within-treatment group changes from prestudy values were tested using the matched-pair {-test. Tests for significant differences between treatment groups were based on analysis of varia nce. the model including terms for treatment, investigator, prior therapy and a prior therapy by treatment interaction. All tests were two-sided with type I error set at a = 0.05.
Results were analysed with respect to both 'worse eye' and 'average eye' (mean of right and left eye). For this purpose, the worse eye was defined as follows:
I. The eye with the greater intraocular pressure at 8 a.m. on day I.
2. If intraocular pressure was equal in both eyes at 8 a.m. on day I, immediately predose. then the worse eye was that with the greater intraocular pressure at 8 a.m. on the day when the intraocular pressure entry criteria were fulfilled.
3. If intraocular pressure was equal in both eyes at 8 a.m. on both day I and the day when the intraocular pressure entry criteria were fulfilled. then the worse eye was defined as the right eye.
Since results for the worse eye and the average eye ana lyses were very similar. only the results for the worse eye analysis are given below. The analysis was based on the 36 patients who completed the study per protoco!.
RESULTS
Thirty-nine patients entered the study. One patient drop ped out of the study for reasons unrelated to test drug administered. Two patients were excluded from analysis because they received oral beta-blockers during the study period. Thirty-six patients completed the study per pro tocol (11-13 patients per centre). There were 12 men and 24 women with a mean age of 63.5 years (range 46-79 years). Prior to the timolol run-in period 21 patients had been on therapy with only a beta-blocker. 10 had pre viously received a beta-blocker plus one or more addi tional agents, and 5 patients had either been on no prior therapy or on non-beta-blocker therapy. The distribution by iris colour was: blue, 18; green, 3; hazel or light golden brown, 4; brown, 8; and dark brown, 3 (these being the five categories into which iris colour had been separated). There were no significant differences between treatment groups with respect to the above parameters. There were 20 patients in the sezolamide treatment group and 16 patients in the placebo group. Table I presents the mean intraocular pressure data and standard deviations for each treatment group. Although intraocular pressures on day I were generally slightly greater for the sezolamide treatment group, these differ ences were not significant. Fig. I depicts graphically the data for 1.8% sezolamide and placebo with respect to mean percentage change in intraocular pressure from day I. In the table and figure, hour a represents 8 a.m., immediately prior to dosing with timolol; hour I is 9 a.m., I hour after the timolol dose and 50 minutes after the study drug instillation; etc. On day 2, the percentage decrease in intraocular pressure from day I (timolol alone) was sig nificant at both 8 and 9 a.m. for sezolamide and placebo administered concurrently with timolol. At I hour after the dose, the decrease demonstrated by sezolamide (15.9%) was significantly greater than that for placebo (6.9%, p = 0.03). On day 8, I hour after the dose, the decrease demonstrated by sezolamide (13.2%) was also significantly different from that for placebo (5.0%, p = 0.04). On day 15, the sezolamide group demonstrated a per centage decrease in intraocular pressure from day I rang ing from 8.0% to 15.5%, which was significant at all times (p<0.05 at 8 a.m.: p<O.O I at 9 a.m. to 8 p.m.) and signifi cantly different from the decrease exhibited by the pla cebo-treated group (3.7-9.0%) at I, 2, 4, 8 and \0 hours after the dose (p<0.01 at hours 1,2 and \0; p = 0.04 at hour 4, and p = 0.05 at hour 8). There was some indication that patients not previously receiving a beta-blocker prior to the run-in period may have responded better to sezola mide than patients receiving a beta-blocker.
Intraocular Pressure
Symptoms
Seven of 20 patients receiving sezolamide reported generally mild, transient local irritation (burning, sting ing, etc.) compared with only I of 16 patients receiving placebo. Seven patients receiving placebo complained of transient, generally mild blurred vision as compared with I patient receiving sezolamide. Both sezolamide and pla cebo were considered reasonably well tolerated by patients.
Evaluation (�l Ophthalmoscopy and Visual Field Behaviour
There were no clinically significant changes with respect to the data of ophthalmoscopic appearance and visual field examination.
COMMENT
Oral carbonic anhydrase inhibitors such as acetazolamide have been available for over three decadeslo and topical non-selective beta-blockers such as timolol for the last 13 years. I I Combination treatment with these agents is often necessary in case of uncontrolled glaucoma. The first authors to study the additive hypotensive effect of oral acetazolamide with timolol were Boger, 1 2 NielsenL1 and Bischoffl4 in 1978. These studies showed that glaucoma patients not controlled by timolol 0.25% or 0.5% alone, could benefit from additional therapy with acetazolamide. Other topical or systemic beta-blockers also demonstrated an additive intraocular pressure-lowering effect when used in combination with systemic carbonic anhydrase inhibitors.15-1 7 An additive intraocular pressure-lowering effect has also been shown when timolol 0.25% was given to patients already receiving oral acetazolamide.
IX
Both carbonic anhydrase inhibitors and beta-blockers appear to reduce intraocular pressure by decreasing aque ous humour formation.
Ill. IY24 Most authors postulate that the two drug classes affect aqueous humour dynamics by different pathways.,Y·25 Investigators have hypothesised that timolol maleate and other beta-adrenergic blockers decrease aqueous humour production by antagonising the effect of circulating catecholamines on the beta-2-adre nergic receptors in the ciliary body. 26 The effect of car bonic anhydrase inhibitors may be mediated by inhibition of carbonic anhydrase isoenzyme II located in the ciliary processes. Bicarbonate synthesis and flow into the pos terior chamber is reduced and this appears to be linked to decreased �odium and fluid movement, resulting in a decreased rate of aqueous humour formation.2 7 .2x Side effects such as burning and stinging are rarely reported for timolol maleate. In this study the local symp toms attributable to sezolamide were generally mild and transient, with no severe or serious adverse reactions.
We conclude that there is an additional statistically sig nificant intraocular pressure-lowering effect, of approxi mately 2 mmHg, when 1.8% sezolamide twice daily is administered adjunctively to patients whose pressures on timolol are in the low twenties. The side effects were tran sient, local and minimal. This study indicates that a com bination of a topical carbonic anhydrase inhibitor and a F. GUNNING ET AL. 
